Drug intelligence / Profile preview

MIND002

Development stage: Unknown
Lead developer: Mind Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

MIND002 is an oral formulation of psilocybin being developed by Mind Pharmaceuticals for the treatment and prevention of headache disorders, including migraine and cluster headaches. As a serotonergic agent, psilocybin acts primarily as an agonist at the 5-HT2A serotonin receptors. The drug is designed as a sub-psychedelic dose therapy, leveraging intellectual property and clinical trial data from Yale University. Mind Pharmaceuticals' strategy for MIND002 focuses on creating scalable clinical delivery models that require minimal psychotherapy, distinguishing it from high-dose psychedelic-assisted therapy models. It is currently being evaluated in Phase 2 clinical trials.

Brand names: Tigrina
Other names: Oral Psilocybinpsilocybin

Targets

HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on MIND002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIND002.

Explore the full profile